BioNexus Gene Lab Corp
General ticker "BGLC" information:
- Sector: Industrials
- Industry: Trading Companies & Distributors
- Capitalization: $7.3M
BioNexus Gene Lab Corp does not follow the US Stock Market performance with the rate: -12.8%.
Estimated limits based on current volatility of 2.0%: low 0.36$, high 0.38$
Factors to consider:
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.26$, 0.73$]
- 2024-12-30 to 2025-12-30 estimated range: [0.19$, 0.58$]
Financial Metrics affecting the BGLC estimates:
- Negative: Operating Income to Revenue ratio of -0.21 <= 0.01
- Negative: Non-GAAP EPS of -0.03 <= 0.11
- Negative: negative Net Income
- Negative: Operating Cash Flow per share of -0.08 <= 0.22
- Negative: Industry Earnings per Price (median) of 0.05 <= 0.06
Short-term BGLC quotes
Long-term BGLC plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $13.36MM | $10.93MM | $9.77MM |
| Operating Expenses | $12.31MM | $11.22MM | $12.36MM |
| Operating Income | $1.06MM | $-0.29MM | $-2.59MM |
| Non-Operating Income | $-0.01MM | $-0.01MM | $-0.01MM |
| Interest Expense | $0.01MM | $0.01MM | $0.01MM |
| Income(Loss) | $1.04MM | $-0.30MM | $-2.61MM |
| Taxes | $0.29MM | $0.05MM | $0.02MM |
| Profit(Loss) | $0.75MM | $-0.36MM | $-2.63MM |
| Stockholders Equity | $7.18MM | $6.67MM | $9.66MM |
| Assets | $9.57MM | $8.74MM | $11.40MM |
| Operating Cash Flow | $0.01MM | $0.54MM | $-1.30MM |
| Investing Cash Flow | $-0.49MM | $-0.45MM | $-0.38MM |
| Financing Cash Flow | $-0.03MM | $0.12MM | $5.75MM |
| Earnings Per Share* | $0.05 | $-0.02 | $-0.17 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.